Shenglin Mei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shenglin Mei has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Ninib Baryawno
Division of Pediatric Oncology and Pediatric Surgery, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
55 shared publications - Peter V. Kharchenko
Altos Labs, San Diego Institute of Science, San Diego, USA
42 shared publications - David Brian Sykes
Massachusetts General Hospital, Boston, MA
40 shared publications - Hirak Sarkar
Vanderbilt University
37 shared publications - Adele Mirna. Alchahin
Division of Pediatric Oncology and Pediatric Surgery, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
36 shared publications - Artem V. Artemov
Institute of Bioengineering, Research Center of Biotechnology RAS, Moscow, Russia
36 shared publications
Latest Publications
- 25 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target
High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase–like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a nonfunctional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.
- 25 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target
High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase–like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a nonfunctional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.
- Open Access
Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis
Prostate cancer is a leading cause of cancer-related mortality in men, and effective treatment options are limited for advanced and metastatic disease. The sialoglycan immune checkpoint Siglec-15 has emerged as a key mediator of tumour-associated immune suppression in several malignancies; however, its expression and functional role in prostate cancer remain poorly defined. Here, using dual immunofluorescence and immunohistochemistry, we demonstrate that Siglec-15 is expressed by prostate tumour epithelial cells, immunosuppressive macrophage phenotypes, and bone-resorbing osteoclasts within the tumour microenvironment. Mechanistically, we show that direct Siglec-15 receptor crosslinking, either by antibodies or tumour cell-derived conditioned medium, promotes monocyte-to-macrophage differentiation, generating macrophages with immunosuppressive and pathogenic phenotypes. Using therapeutic antibodies, we show that Siglec-15 blockade suppresses supernatant-induced monocyte to macrophage differentiation, allowing for the recovery of CD8⁺ T-cell activation. Furthermore, we reveal that macrophage colony-stimulating factor (M-CSF) driven monocyte-derived macrophage differentiation is partially dependent on Siglec-15 signalling, with Siglec-15 blockade enhancing CD8⁺ T-cell responses. In addition, anti-Siglec-15 treatment suppressed osteoclast differentiation, highlighting a dual role for Siglec-15 in prostate cancer immune suppression and bone remodelling. Consistent with these in vitro findings, therapeutic Siglec-15 blockade significantly reduced subcutaneous tumour growth in a CD8⁺ T-cell-dependent manner and prolonged survival in a mouse model of prostate cancer metastasis. Together, these findings identify Siglec-15 as a central regulator of the prostate cancer glyco-immune axis, linking tumour-associated macrophage immune suppression with osteoclast-mediated bone remodelling, providing a compelling rationale for the clinical development of Siglec-15-targeted therapies for patients with advanced disease.
Open AccessSiglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis
Prostate cancer is a leading cause of cancer-related mortality in men, and effective treatment options are limited for advanced and metastatic disease. The sialoglycan immune checkpoint Siglec-15 has emerged as a key mediator of tumour-associated immune suppression in several malignancies; however, its expression and functional role in prostate cancer remain poorly defined. Here, using dual immunofluorescence and immunohistochemistry, we demonstrate that Siglec-15 is expressed by prostate tumour epithelial cells, immunosuppressive macrophage phenotypes, and bone-resorbing osteoclasts within the tumour microenvironment. Mechanistically, we show that direct Siglec-15 receptor crosslinking, either by antibodies or tumour cell-derived conditioned medium, promotes monocyte-to-macrophage differentiation, generating macrophages with immunosuppressive and pathogenic phenotypes. Using therapeutic antibodies, we show that Siglec-15 blockade suppresses supernatant-induced monocyte to macrophage differentiation, allowing for the recovery of CD8⁺ T-cell activation. Furthermore, we reveal that macrophage colony-stimulating factor (M-CSF) driven monocyte-derived macrophage differentiation is partially dependent on Siglec-15 signalling, with Siglec-15 blockade enhancing CD8⁺ T-cell responses. In addition, anti-Siglec-15 treatment suppressed osteoclast differentiation, highlighting a dual role for Siglec-15 in prostate cancer immune suppression and bone remodelling. Consistent with these in vitro findings, therapeutic Siglec-15 blockade significantly reduced subcutaneous tumour growth in a CD8⁺ T-cell-dependent manner and prolonged survival in a mouse model of prostate cancer metastasis. Together, these findings identify Siglec-15 as a central regulator of the prostate cancer glyco-immune axis, linking tumour-associated macrophage immune suppression with osteoclast-mediated bone remodelling, providing a compelling rationale for the clinical development of Siglec-15-targeted therapies for patients with advanced disease.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S3. TH-MYCN tumor microenvironment is composed of Schwannian and mesenchymal stroma, and a diverse immune-cell repertoire. Related to Figures 2 and 3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S3. TH-MYCN tumor microenvironment is composed of Schwannian and mesenchymal stroma, and a diverse immune-cell repertoire. Related to Figures 2 and 3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Table S1 shows characteristics of TH-MYCN mouse samples used for tumoroid cultures, scRNA-seq and immunostainings.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Table S1 shows characteristics of TH-MYCN mouse samples used for tumoroid cultures, scRNA-seq and immunostainings.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S9. Immunofluorescence staining of hemizygous TH-MYCN tumors and matched ex vivo tumoroids. Related to Figure 4.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S9. Immunofluorescence staining of hemizygous TH-MYCN tumors and matched ex vivo tumoroids. Related to Figure 4.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S5. Identification of malignant cells by inferCNV. Related to Figure 3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S5. Identification of malignant cells by inferCNV. Related to Figure 3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S4. Tumor hallmark gene expression patterns in human and mouse tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S4. Tumor hallmark gene expression patterns in human and mouse tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S15. Cross-species integration analysis of common cell clusters. Related to Figure 5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S15. Cross-species integration analysis of common cell clusters. Related to Figure 5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S13. Survival probability for neuroblastoma patients non-MYCN amplified tumors with tumoroid enriched gene expression programs. Related to Figure 5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S13. Survival probability for neuroblastoma patients non-MYCN amplified tumors with tumoroid enriched gene expression programs. Related to Figure 5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S14. Survival probability for neuroblastoma patients MYCN amplified tumors with tumoroid enriched gene expression programs. Related to Figure 5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State
Figure S14. Survival probability for neuroblastoma patients MYCN amplified tumors with tumoroid enriched gene expression programs. Related to Figure 5.